Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
ANN ARBOR, Mich., June 15, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented results from an analysis comparing the cardiovascular risk reduction benefits of bempedoic acid treatment with statin therapy per unit decrease in LDL-C, as …
 
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
  
 
     
     
     
     
     
     
     
     
     
     
     
    